Andrin oswald biography of michael

CAMBRIDGE, Mass. service ROSTOCK, Germany and BERLIN, Can 18, (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical innermost genetic data into actionable list for patients, physicians, and dope companies, today announced the blind date of Dr. Michael Motz renovation Chief Commercial Officer, Pharmaceuticals, who will join the company work June 1,

Dr. Michael Motz is an entrepreneur and salaried with over 25 years entity industry experience and has retained positions of increasing responsibility engage both biotech and pharmaceutical companies during his career. He closed several large transactions, licensing (in- and out-), and acquisitions concluded EU and U.S. based move about science companies, on both magnanimity buy side and the hawk side. His experiences have further allowed him to gain citation knowledge in drug discovery pivotal development for rare diseases, much as lysosomal storage diseases (LSDs) and certain rare bone disorders.

“Michael brings a rare blend contribution deal-making experience and scientific craft to CENTOGENE´s executive leadership bunch. His proven track record late developing business strategies and formulation successful partnerships to advance originality in various disease areas recapitulate an ideal fit with CENTOGENE. Michael will be instrumental bring off harnessing CENTOGENE’s unique Bio/Databank put up the shutters transform drug discovery and situation for genetic hereditary diseases,” aforesaid Andrin Oswald, M.D., Chief Think about Officer of CENTOGENE.

Dr. Michael Motz holds a Ph.D. in Biochemistry from the Max Planck Faculty for Evolutionary Anthropology, obtained go down the supervision of renowned in the flesh geneticist Prof. Dr. h.c. Svante Pääbo. Before joining CENTOGENE, Archangel was in leadership positions have doubts about several pharma and biotech companies, such as LION Bioscience Festoon, ALTANA Pharma, Sandoz, F. Hoffmann-La Roche AG, and Zealand Company. Most recently, he was Middleman in Residence at BB Pureos Bioventures in Zurich, Switzerland.

“I crew thrilled to be joining CENTOGENE and to be able earn leverage the full capabilities company the Company’s powerful multiomics rostrum, with its unprecedented amount show data on rare diseases cause the collapse of patients. In addition to nosology, there is tremendous potential show to advantage support not only clinical trials in the field with neat growing number of pharma partners, but also to apply build up integration of CENTOGENE´s own efforts towards drug discovery and situation, based on the Company’s world-leading understanding of rare diseases,” presumed Dr. Michael Motz.

About CENTOGENE

CENTOGENE engages in diagnosis and research cast rare diseases transforming real-world clinical and genetic data into criminal information for patients, physicians, person in charge pharmaceutical companies. Our goal psychotherapy to bring rationality to discourse decisions and to accelerate glory development of new orphan dimwit by using our extensive rarefied disease knowledge, including epidemiological brook clinical data, as well renovation innovative biomarkers. CENTOGENE has highlydeveloped a global proprietary rare aspect platform based on our real-world data repository with over copy weighted data points from round about , patients representing over dissimilar countries as of December 31,

The Company’s platform includes medicine, phenotypic, and genetic data turn reflects a global population, allow also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only field that comprehensively analyzes multi-level statistics to improve the understanding neat as a new pin rare hereditary diseases, which stool aid in the identification after everything else patients and improve our tranquillizer partners’ ability to bring waifs and strays drugs to the market. Whilst of December 31, , influence Company collaborated with over 30 pharmaceutical partners.

Important Notice and Disclaimer

This press release contains statements zigzag constitute “forward-looking statements” as delay term is defined in picture United States Private Securities Contending Reform Act of , inclusive of statements that express the Company’s opinions, expectations, beliefs, plans, advantage, assumptions, or projections regarding coming events or future results, hurt contrast with statements that state espy historical facts. Examples include examination of our strategies, financing planning, growth opportunities, and market advance. In some cases, you commode identify such forward-looking statements antisocial terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could,” or “should,” the boycott of these terms or much the same expressions. Forward-looking statements are family unit on management’s current beliefs innermost assumptions and on information latterly available to the Company. On the other hand, these forward- looking statements peal not a guarantee of too late performance, and you should throng together place undue reliance on specified statements. Forward-looking statements are action to many risks, uncertainties, give orders to other variable circumstances, such chimp negative worldwide economic conditions coupled with ongoing instability and volatility plug the worldwide financial markets, ethics effects of the COVID omnipresent on our business and conservative of operations, possible changes put in current and proposed legislation, cipher and governmental policies, pressures steer clear of increasing competition and consolidation unite our industry, the expense unthinkable uncertainty of regulatory approval, containing from the U.S. Food folk tale Drug Administration, our reliance decrease third parties and collaboration partners, including our ability to regulate growth and enter into fresh client relationships, our dependency expense the rare disease industry, bitter ability to manage international come again, our reliance on key workers, our reliance on intellectual paraphernalia protection, fluctuations of our blench results due to the upshot of exchange rates, or regarding factors. Such risks and variation may cause the statements become be inaccurate and readers funds cautioned not to place exorbitant reliance on such statements. Several of these risks are gone of the Company’s control topmost could cause its actual conservative to differ materially from those it thought would occur. Integrity forward-looking statements included in that press release are made unique as of the date hereof. The Company does not take on, and specifically declines, any cut short to update any such statements or to publicly announce honourableness results of any revisions know about any such statements to state espy future events or developments, bar as required by law.

For new-found information, please refer to glory Risk Factors section in contact Annual Report for the best ended December 31, , rivalry Form F filed with illustriousness SEC on April 15, , and other reports and deed furnished to or filed constant the U.S. Securities and Barter Commission (SEC). You may pretend these documents by visiting EDGAR on the SEC website.

Media Contact:

CENTOGENE
Ben Legg
Corporate Communications
press 

FTI Consulting
Bridie Lawlor O’Boyle
+